Archive Opens in a new window
API Opens in a new window
Back to MCD Search

National Coverage Determination (NCD)

Glycated Hemoglobin/Glycated Protein

190.21

Expand All | Collapse All

Tracking Information

Publication Number
100-3
Manual Section Number
190.21
Manual Section Title
Glycated Hemoglobin/Glycated Protein
Version Number
1
Effective Date of this Version
11/25/2002
Ending Effective Date of this Version
Implementation Date
01/01/2003
Implementation QR Modifier Date

Description Information

Benefit Category
Diagnostic Laboratory Tests


Please Note: This may not be an exhaustive list of all applicable Medicare benefit categories for this item or service.

Item/Service Description

The management of diabetes mellitus requires regular determinations of blood glucose levels. Glycated hemoglobin/protein levels are used to assess long-term glucose control in diabetes. Alternative names for these tests include glycated or glycosylated hemoglobin or Hgb, hemoglobin glycated or glycosylated protein, and fructosamine.

Glycated hemoglobin (equivalent to hemoglobin A1) refers to total glycosylated hemoglobin present in erythrocytes, usually determined by affinity or ion-exchange chromatographic methodology. Hemoglobin A1c refers to the major component of hemoglobin A1, usually determined by ion-exchange affinity chromatography, immunoassay or agar gel electrophoresis. Fructosamine or glycated protein refers to glycosylated protein present in a serum or plasma sample. Glycated protein refers to measurement of the component of the specific protein that is glycated usually by colorimetric method or affinity chromatography.

Glycated hemoglobin in whole blood assesses glycemic control over a period of 4-8 weeks and appears to be the more appropriate test for monitoring a patient who is capable of maintaining long-term, stable control. Measurement may be medically necessary every 3 months to determine whether a patient's metabolic control has been on average within the target range. More frequent assessments, every 1-2 months, may be appropriate in the patient whose diabetes regimen has been altered to improve control or in whom evidence is present that intercurrent events may have altered a previously satisfactory level of control (for example, post-major surgery or as a result of glucocorticoid therapy). Glycated protein in serum/plasma assesses glycemic control over a period of 1-2 weeks. It may be reasonable and necessary to monitor glycated protein monthly in pregnant diabetic women. Glycated hemoglobin/protein test results may be low, indicating significant, persistent hypoglycemia, in nesidioblastosis or insulinoma, conditions which are accompanied by inappropriate hyperinsulinemia. A below normal test value is helpful in establishing the patient's hypoglycemic state in those conditions.
Indications and Limitations of Coverage

Indications

Glycated hemoglobin/protein testing is widely accepted as medically necessary for the management and control of diabetes. It is also valuable to assess hyperglycemia, a history of hyperglycemia or dangerous hypoglycemia. Glycated protein testing may be used in place of glycated hemoglobin in the management of diabetic patients, and is particularly useful in patients who have abnormalities of erythrocytes such as hemolytic anemia or hemoglobinopathies.

Limitations

It is not considered reasonable and necessary to perform glycated hemoglobin tests more often than every three months on a controlled diabetic patient to determine whether the patient's metabolic control has been on average within the target range. It is not considered reasonable and necessary for these tests to be performed more frequently than once a month for diabetic pregnant women. Testing for uncontrolled type one or two diabetes mellitus may require testing more than four times a year. The above Description Section provides the clinical basis for those situations in which testing more frequently than four times per annum is indicated, and medical necessity documentation must support such testing in excess of the above guidelines.

Many methods for the analysis of glycated hemoglobin show significant interference from elevated levels of fetal hemoglobin or by variant hemoglobin molecules. When the glycated hemoglobin assay is initially performed in these patients, the laboratory may inform the ordering physician of a possible analytical interference. Alternative testing, including glycated protein, for example, fructosamine, may be indicated for the monitoring of the degree of glycemic control in this situation. It is therefore conceivable that a patient will have both a glycated hemoglobin and glycated protein ordered on the same day. This should be limited to the initial assay of glycated hemoglobin, with subsequent exclusive use of glycated protein. These tests are not considered to be medically necessary for the diagnosis of diabetes.

Note: Scroll down for links to the quarterly Covered Code Lists (including narrative).

Cross Reference

Also see the Medicare Claims Processing Manual Opens in a new window, Chapter 120, Clinical Laboratory Services Based on Negotiated Rulemaking.
Claims Processing Instructions

Transmittal Information

Transmittal Number
17
Coverage Transmittal Link
https://www.cms.gov/Regulations-and-Guidance/Guidance/Transmittals/Downloads/r17ncd.pdf Opens in a new window
Revision History

07/2004 - Published NCD in the NCD Manual without change to narrative contained in PM AB-02-110. Coding guidance now published in Medicare Lab NCD Manual. Effective and Implementation dates NA. (TN 17 Opens in a new window) (CR 2130)

07/2002 - Implemented NCD. Effective date 11/25/02. Implementation date 1/01/03. (TN AB-02-110 Opens in a new window) (CR 2130)
Other

Covered Code Lists (including narrative)

January 2025 (PDF) (ICD-10 Opens in a new window)
October 2024 (PDF) (ICD-10 Opens in a new window)
July 2024 (PDF) (ICD-10 Opens in a new window)
April 2024 (PDF) (ICD-10 Opens in a new window)
January 2024 (PDF) (ICD-10 Opens in a new window)
October 2023 (PDF) (ICD-10 Opens in a new window)
July 2023 (PDF) (ICD-10 Opens in a new window)
April 2023 (PDF) (ICD-10 Opens in a new window)
January 2023 (PDF) (ICD-10 Opens in a new window)
October 2022 (PDF) (ICD-10 Opens in a new window)
July 2022 (PDF) (ICD-10 Opens in a new window)
April 2022 (PDF) (ICD-10 Opens in a new window)
January 2022 (PDF) (ICD-10 Opens in a new window)
October 2021 (PDF) (ICD-10 Opens in a new window)
July 2021 (PDF) (ICD-10 Opens in a new window)
April 2021 (PDF) (ICD-10 Opens in a new window)
January 2021 (PDF) (ICD-10 Opens in a new window)
October 2020 (PDF) (ICD-10 Opens in a new window)
July 2020 (PDF) (ICD-10 Opens in a new window)
April 2020 (PDF) (ICD-10 Opens in a new window)
January 2020 (PDF) (ICD-10 Opens in a new window)
October 2019 (PDF) (ICD-10 Opens in a new window)
July 2019 (PDF) (ICD-10 Opens in a new window)
April 2019 (PDF) (ICD-10 Opens in a new window)
January 2019 (PDF) (ICD-10 Opens in a new window)
October 2018 (PDF) (ICD-10 Opens in a new window)
July 2018 (PDF) (ICD-10 Opens in a new window)
April 2018 (PDF) (ICD-10 Opens in a new window)
January 2018 (ICD-10 Opens in a new window)
October 2017 (ICD-10 Opens in a new window)
July 2017 (ICD-10 Opens in a new window)
April 2017 (ICD-10 Opens in a new window)
January 2017 (ICD-10 Opens in a new window)
October 2016 (ICD-10 Opens in a new window)
January 2016 (ICD-10 Opens in a new window)
October 2015 (ICD-10 Opens in a new window, ICD-9 Opens in a new window)
October 2014 (ICD-10 Opens in a new window, ICD-9 Opens in a new window)

Changes to Lab NCD Edit Software

January 2025 Opens in a new window
October 2024 Opens in a new window
July 2024 Opens in a new window
January 2024 Opens in a new window
October 2023 Opens in a new window
April 2023 Opens in a new window
January 2023 Opens in a new window
October 2022 Opens in a new window
April 2022 Opens in a new window
January 2022 Opens in a new window
October 2021 Opens in a new window
July 2021 Opens in a new window
October 2020 Opens in a new window
April 2020 Opens in a new window
January 2020 Opens in a new window
October 2019 Opens in a new window
July 2019 Opens in a new window
January 2019 Opens in a new window
October 2018 Opens in a new window
April 2018 Opens in a new window
January 2018 Opens in a new window
July 2017 Opens in a new window
April 2017 Opens in a new window
January 2017 Opens in a new window
January 2016 Opens in a new window
October 2014 Opens in a new window

National Coverage Analyses (NCAs)

This NCD has been or is currently being reviewed under the National Coverage Determination process. The following are existing associations with NCAs, from the National Coverage Analyses database.

Coding Analyses for Labs (CALs)

Additional Information

Other Versions
Title Version Effective Between View the document version
Glycated Hemoglobin/Glycated Protein 1 11/25/2002 - N/A You are here
CPT Copyright Statement
CPT only copyright 2002-2011 American Medical Association. All rights reserved. CPT is a registered trademark of the American Medical Association. Applicable FARS/DFARS Apply to Government Use. Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein.
Reasons for Denial
Note: This section has not been negotiated by the Negotiated RuleMaking Committee. It includes CMS’s interpretation of it’s longstanding policies and is included for informational purposes. Tests for screening purposes that are performed in the absense of signs, symptoms, complaints, or personal history of disease or injury are not covered except as explicity authorized by statue. These include exams required by insurance companies, business establishments, government agencies, or other third parties. Tests that are not reasonable and necessary for the diagnosis or treatment of an illness or injury are not covered according to the statue. Failure to provide documentation of the medical necessity of tests may result in denial of claims. The documentation may include notes documenting relevant signs, symptoms, or abnormal findings that substantiate the medical necessity for ordering the tests. In addition, failure to provide independent verification that the test was ordered by the treating physician (or qualified nonphysician practitioner) through documentation in the physician’s office may result in denial. A claim for a test for which there is a national coverage or local medical review policy will be denied as not reasonable and necessary if it is submitted without an ICD-9-CM code or narrative diagnosis listed as covered in the policy unless other medical documentation justifying the necessity is submitted with the claim. If a national or local policy identifies a frequency expectation, a claim for a test that exceeds that expectation may be denied as not reasonable and necessary, unless it is submitted with documentation justifying increased frequency. Tests that are not ordered by a treating physician or other qualified treating nonphysician practitioner acting within the scope of their license and in compliance with Medicare requirements will be denied as not reasonable and necessary. Failure of the laboratory performing the test to have the appropriate Clinical Laboratory Improvement Act of 1988 (CLIA) certificate for the testing performed will result in denial of claims.
Submit Feedback/Ask a Question